Private practice with Dr Seth Bilazarian http://blogs.theheart.org/private-practice Clinical and interventional cardiologist, Seth Bilazarian MD, animates this forum for issues faced in private practice cardiology. en-us theheart.org theheart.org info@theheart.org http://blogs.theheart.org/images/private-practice/rss_banner_url.jpg Clinical and interventional cardiologist, Seth Bilazarian MD, animates this forum for issues faced in private practice cardiology. http://blogs.theheart.org/private-practice Corporate donations, Susan G Komen, and Kentucky Fried Chicken Private practice with Dr Seth Bilazarian info@theheart.org What can we learn from the Susan G Komen/Planned Parenthood grants debacle?<img src="http://feeds.feedburner.com/~r/private-practice/~4/J9ag2lFG0Lw" height="1" width="1"/> What can we learn from the Susan G Komen/Planned Parenthood grants debacle?

See also:

]]> Fri, 03 Feb 2012 12:20:00 -0500 http://feedproxy.google.com/~r/private-practice/~3/J9ag2lFG0Lw/corporate-donations-susan-g-komen-and-kentucky-fried-chicken http://blogs.theheart.org/private-practice/2012/2/3/corporate-donations-susan-g-komen-and-kentucky-fried-chicken http://blogs.theheart.org/private-practice/2012/2/3/corporate-donations-susan-g-komen-and-kentucky-fried-chicken#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/corporate-donations-susan-g-komen-and-kentucky-fried-chicken.jpg 0 http://blogs.theheart.org/private-practice/2012/2/3/corporate-donations-susan-g-komen-and-kentucky-fried-chicken Appropriate-use criteria for coronary revascularization: What's appropriate, unknown, inappropriate? Private practice with Dr Seth Bilazarian info@theheart.org The intentions of the new guidelines are laudable.<img src="http://feeds.feedburner.com/~r/private-practice/~4/wz94_s6keEk" height="1" width="1"/> The intentions of the new guidelines are laudable.

Appropriate: It's appropriate for the professional societies to address this issue.

Unknown: It's unknown whether the guidelines are recommendations or rules.

Inappropriate: It's definitely inappropriate when concepts such as appropriateness, malfeasance, fraud, or even felony are confused in popular discourse.

What do you think?

See:

ACCF /SCAI/STS /AATS /AHA /ASNC /HFSA /SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update

]]> Mon, 30 Jan 2012 17:00:00 -0500 http://feedproxy.google.com/~r/private-practice/~3/wz94_s6keEk/appropriate-use-criteria-for-coronary-revascularization-appropriate-unknown-inappropriate http://blogs.theheart.org/private-practice/2012/1/30/appropriate-use-criteria-for-coronary-revascularization-appropriate-unknown-inappropriate http://blogs.theheart.org/private-practice/2012/1/30/appropriate-use-criteria-for-coronary-revascularization-appropriate-unknown-inappropriate#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/appropriate-use-criteria-for-coronary-revascularization-appropriate-unknown-inappropriate.jpg 2 http://blogs.theheart.org/private-practice/2012/1/30/appropriate-use-criteria-for-coronary-revascularization-appropriate-unknown-inappropriate Statins in 'healthy' patients: Blumenthal vs Redberg Private practice with Dr Seth Bilazarian info@theheart.org The Wall Street Journal’s debate, which pitted Dr Rita Redberg against Dr Roger Blumenthal on the issue of statins for 'healthy' patients, raises numerous questions including how to define a healthy patient. Does feeling healthy constitute being healthy?<img src="http://feeds.feedburner.com/~r/private-practice/~4/Z3A8AENPOSE" height="1" width="1"/> The Wall Street Journal’s debate, which pitted Dr Rita Redberg against Dr Roger Blumenthal on the issue of statins for "healthy" patients, raises numerous questions including how to define a healthy patient. Does feeling healthy constitute being healthy?

What are your thoughts on this debate?

See:

Should Healthy People Take Cholesterol Drugs to Prevent Heart Disease?

To prescribe or not to prescribe: That is the statin question, experts debate

]]> Tue, 24 Jan 2012 08:40:00 -0500 http://feedproxy.google.com/~r/private-practice/~3/Z3A8AENPOSE/statins-in-healthy-patients-blumenthal-vs-redberg http://blogs.theheart.org/private-practice/2012/1/24/statins-in-healthy-patients-blumenthal-vs-redberg http://blogs.theheart.org/private-practice/2012/1/24/statins-in-healthy-patients-blumenthal-vs-redberg#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/statins-in-healthy-patients-blumenthal-vs-redberg.jpg 11 http://blogs.theheart.org/private-practice/2012/1/24/statins-in-healthy-patients-blumenthal-vs-redberg Struggling with the sustainable-growth-rate "hole" (and potentially massive cuts) Private practice with Dr Seth Bilazarian info@theheart.org The very real threat of Medicare cuts of 27% beginning on January 1 is a ticking time bomb for private practices across the US. Do we envisage fee revisions? Staff cuts? Join the wave of private practitioners seeking relief from ongoing financial ...<img src="http://feeds.feedburner.com/~r/private-practice/~4/0DlkuibH8Io" height="1" width="1"/> The very real threat of Medicare cuts of 27% beginning on January 1 is a ticking time bomb for private practices across the US. Do we envisage fee revisions? Staff cuts? Join the wave of private practitioners seeking relief from ongoing financial uncertainty through hospital employment?

How are you riding this storm?

See:

 

]]> Thu, 22 Dec 2011 09:25:00 -0500 http://feedproxy.google.com/~r/private-practice/~3/0DlkuibH8Io/struggling-with-the-sustainable-growth-rate-hole-and-potentially-massive-cuts http://blogs.theheart.org/private-practice/2011/12/22/struggling-with-the-sustainable-growth-rate-hole-and-potentially-massive-cuts http://blogs.theheart.org/private-practice/2011/12/22/struggling-with-the-sustainable-growth-rate-hole-and-potentially-massive-cuts#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/struggling-with-the-sustainable-growth-rate-hole-and-potentially-massive-cuts.jpg 1 http://blogs.theheart.org/private-practice/2011/12/22/struggling-with-the-sustainable-growth-rate-hole-and-potentially-massive-cuts Calling all "bottom-feeder interventionalists" who provide PCI without SOS Private practice with Dr Seth Bilazarian info@theheart.org The tone of some respondents to the recent PCI survey jointly conducted by theheart.org and US News & World Report strikes a nerve.<img src="http://feeds.feedburner.com/~r/private-practice/~4/_8q-h9KQuxg" height="1" width="1"/> The tone of some respondents to the recent PCI survey jointly conducted by theheart.org and US News & World Report strikes a nerve.

See:

 

]]> Tue, 13 Dec 2011 10:25:00 -0500 http://feedproxy.google.com/~r/private-practice/~3/_8q-h9KQuxg/calling-all-bottomfeeder-interventionalists-who-provide-pci-without-sos http://blogs.theheart.org/private-practice/2011/12/13/calling-all-bottomfeeder-interventionalists-who-provide-pci-without-sos http://blogs.theheart.org/private-practice/2011/12/13/calling-all-bottomfeeder-interventionalists-who-provide-pci-without-sos#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/calling-all-bottomfeeder-interventionalists-who-provide-pci-without-sos.jpg 6 http://blogs.theheart.org/private-practice/2011/12/13/calling-all-bottomfeeder-interventionalists-who-provide-pci-without-sos Making sense of patient compliance Private practice with Dr Seth Bilazarian info@theheart.org The HOOPS and MI FREEE trials presented here at AHA 2011 delve into the enigma of patient compliance and present confounding results.<img src="http://feeds.feedburner.com/~r/private-practice/~4/laor5CUGztM" height="1" width="1"/> The HOOPS and MI FREEE trials presented here at AHA 2011 delve into the enigma of patient compliance and present confounding results.

See:

 

]]> Wed, 16 Nov 2011 20:55:00 -0500 http://feedproxy.google.com/~r/private-practice/~3/laor5CUGztM/making-sense-of-patient-compliance http://blogs.theheart.org/private-practice/2011/11/16/making-sense-of-patient-compliance http://blogs.theheart.org/private-practice/2011/11/16/making-sense-of-patient-compliance#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/making-sense-of-patient-compliance.jpg 2 aha 2011 aha 2011 http://blogs.theheart.org/private-practice/2011/11/16/making-sense-of-patient-compliance When to bridge patients on long-term anticoagulation Private practice with Dr Seth Bilazarian info@theheart.org Dr Sam Goldhaber gave clarity here at AHA 2011 to the complicated issue of when to bridge patients who are on long-term anticoagulation and need to undergo invasive procedures such as cataract surgery, dental extraction, and colonoscopy.<img src="http://feeds.feedburner.com/~r/private-practice/~4/e-VRlSN7V3Q" height="1" width="1"/> Dr Sam Goldhaber gave clarity here at AHA 2011 to the complicated issue of when to bridge patients who are on long-term anticoagulation and need to undergo invasive procedures such as cataract surgery, dental extraction, and colonoscopy.

See:

 

]]> Wed, 16 Nov 2011 10:15:00 -0500 http://feedproxy.google.com/~r/private-practice/~3/e-VRlSN7V3Q/when-to-bridge-patients-on-longterm-anticoagulation http://blogs.theheart.org/private-practice/2011/11/16/when-to-bridge-patients-on-longterm-anticoagulation http://blogs.theheart.org/private-practice/2011/11/16/when-to-bridge-patients-on-longterm-anticoagulation#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/when-to-bridge-patients-on-longterm-anticoagulation.jpg 0 aha 2011 aha 2011 http://blogs.theheart.org/private-practice/2011/11/16/when-to-bridge-patients-on-longterm-anticoagulation Niacin in AIM-HIGH: What implications for the practitioner? Private practice with Dr Seth Bilazarian info@theheart.org The conclusion from the AIM-HIGH trial is relatively straight-forward: niacin for secondary prevention didn't work for any of the patient subgroups in the study. What are the implications of these results for your practice?<img src="http://feeds.feedburner.com/~r/private-practice/~4/YZ7Id-hon-Q" height="1" width="1"/> The conclusion from the AIM-HIGH trial is relatively straight-forward: niacin for secondary prevention didn't work for any of the patient subgroups in the study. What are the implications of these results for your practice?

To read a summary of the trial and my interpretation, download this slideset.

See:

]]> Tue, 15 Nov 2011 11:20:00 -0500 http://feedproxy.google.com/~r/private-practice/~3/YZ7Id-hon-Q/niacin-niaspan-in-aim-high-what-implications-for-the-practitioner http://blogs.theheart.org/private-practice/2011/11/15/niacin-niaspan-in-aim-high-what-implications-for-the-practitioner http://blogs.theheart.org/private-practice/2011/11/15/niacin-niaspan-in-aim-high-what-implications-for-the-practitioner#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/niacin-niaspan-in-aim-high-what-implications-for-the-practitioner.jpg 4 aha 2011 aha 2011 http://blogs.theheart.org/private-practice/2011/11/15/niacin-niaspan-in-aim-high-what-implications-for-the-practitioner Rivaroxaban (Xarelto) in ACS: Calculating net clinical benefit Private practice with Dr Seth Bilazarian info@theheart.org Rivaroxaban (Xarelto) in ACS: Calculating net clinical benefit. ATLAS ACS 2 is important news in Orlando but beyond the headlines, what is the net clinical benefit of Xarelto in ACS?<img src="http://feeds.feedburner.com/~r/private-practice/~4/hRvTPLedtvc" height="1" width="1"/> ATLAS ACS 2 is important news in Orlando but beyond the headlines, what is the net clinical benefit of Xarelto in ACS? 

To read a summary of the trial and my interpretation, download this slideset.

See:

 

]]> Mon, 14 Nov 2011 09:10:00 -0500 http://feedproxy.google.com/~r/private-practice/~3/hRvTPLedtvc/rivaroxabanxarelto-net-clinical-benefit http://blogs.theheart.org/private-practice/2011/11/14/rivaroxabanxarelto-net-clinical-benefit http://blogs.theheart.org/private-practice/2011/11/14/rivaroxabanxarelto-net-clinical-benefit#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/rivaroxabanxarelto-net-clinical-benefit.jpg 0 aha 2011 aha 2011 http://blogs.theheart.org/private-practice/2011/11/14/rivaroxabanxarelto-net-clinical-benefit Adopting rivaroxaban (Xarelto): The pros and the cons Private practice with Dr Seth Bilazarian info@theheart.org Now that Xarelto has been FDA approved and is becoming available in pharmacies across the US, how should we adopt this new drug?<img src="http://feeds.feedburner.com/~r/private-practice/~4/XBf4pgy2WTA" height="1" width="1"/> Now that Xarelto has been FDA approved and is becoming available in pharmacies across the US, how should we adopt this new drug?

To read my comparative review of the literature, download this slideset.

See:

]]> Tue, 08 Nov 2011 16:28:00 -0500 http://feedproxy.google.com/~r/private-practice/~3/XBf4pgy2WTA/adopting-rivaroxaban-xarelto-the-pros-and-the-cons http://blogs.theheart.org/private-practice/2011/11/8/adopting-rivaroxaban-xarelto-the-pros-and-the-cons http://blogs.theheart.org/private-practice/2011/11/8/adopting-rivaroxaban-xarelto-the-pros-and-the-cons#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/adopting-rivaroxaban-xarelto-the-pros-and-the-cons.jpg 6 http://blogs.theheart.org/private-practice/2011/11/8/adopting-rivaroxaban-xarelto-the-pros-and-the-cons Navigating referral mayhem Private practice with Dr Seth Bilazarian info@theheart.org In a competitive healthcare environment where—at least in the Boston area—there is an abundance of tertiary-care facilities, what is the best way to counsel your patient and make the right referral?<img src="http://feeds.feedburner.com/~r/private-practice/~4/YinU38-fYjs" height="1" width="1"/> In a competitive healthcare environment where—at least in the Boston area—there is an abundance of tertiary-care facilities, what is the best way to counsel your patient and make the right referral?

]]> Thu, 13 Oct 2011 11:45:00 -0400 http://feedproxy.google.com/~r/private-practice/~3/YinU38-fYjs/navigating-referral-mayhem http://blogs.theheart.org/private-practice/2011/10/13/navigating-referral-mayhem http://blogs.theheart.org/private-practice/2011/10/13/navigating-referral-mayhem#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/navigating-referral-mayhem.jpg 2 http://blogs.theheart.org/private-practice/2011/10/13/navigating-referral-mayhem ACLS and BLS: Getting recertification wrong Private practice with Dr Seth Bilazarian info@theheart.org The American Heart Association's approach to recertification for ACLS (advance cardiac life support) and BLS (basic life support) is a frustrating exercise and a misuse of a physician's time.<img src="http://feeds.feedburner.com/~r/private-practice/~4/tTxHdXKlXNQ" height="1" width="1"/> The American Heart Association's approach to recertification for ACLS (advance cardiac life support) and BLS (basic life support) is a frustrating exercise and a misuse of a physician's time.

Do you share the frustration?

See also:

Does board recertification ensure standards of practice? Or is it now an exercise in liability control?

]]> Tue, 04 Oct 2011 09:15:00 -0400 http://feedproxy.google.com/~r/private-practice/~3/tTxHdXKlXNQ/acls-and-bls-getting-recertification-wrong http://blogs.theheart.org/private-practice/2011/9/27/acls-and-bls-getting-recertification-wrong http://blogs.theheart.org/private-practice/2011/9/27/acls-and-bls-getting-recertification-wrong#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/acls-and-bls-getting-recertification-wrong.jpg 8 http://blogs.theheart.org/private-practice/2011/9/27/acls-and-bls-getting-recertification-wrong Atorvastatin (Lipitor): The countdown to November Private practice with Dr Seth Bilazarian info@theheart.org With the results of the SATURN trial indicating a tie between atorvastatin and rosuvastatin in patients with documented coronary disease, is there any reason for not switching all patients to atorvastatin once it becomes available in generic form?<img src="http://feeds.feedburner.com/~r/private-practice/~4/s2qdhnOPBM8" height="1" width="1"/> With the results of the SATURN trial indicating a tie between atorvastatin and rosuvastatin in patients with documented coronary disease, is there any reason for not switching all patients to atorvastatin—except those who are intolerant or don't reach the treatment goal with it—once it becomes available in a generic form in November?

Has SATURN influenced your prescribing practice? Will there be a continued role for simvastatin?

See also:

 

]]> Thu, 22 Sep 2011 15:20:00 -0400 http://feedproxy.google.com/~r/private-practice/~3/s2qdhnOPBM8/atorvastatin-lipitor-the-countdown-to-november http://blogs.theheart.org/private-practice/2011/9/22/atorvastatin-lipitor-the-countdown-to-november http://blogs.theheart.org/private-practice/2011/9/22/atorvastatin-lipitor-the-countdown-to-november#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/atorvastatin-lipitor-the-countdown-to-november.jpg 9 http://blogs.theheart.org/private-practice/2011/9/22/atorvastatin-lipitor-the-countdown-to-november Apixaban vs rivaroxaban vs dabigatran vs warfarin Private practice with Dr Seth Bilazarian info@theheart.org Apixaban vs rivaroxaban vs dabigatran vs warfarin. With a wealth of data on the novel anticoagulants now available, it's time to hunker down and figure out what's best for our patients.<img src="http://feeds.feedburner.com/~r/private-practice/~4/ueGP-5ywMbU" height="1" width="1"/> With a wealth of data on the novel anticoagulants now available, it's time to hunker down and figure out what's best for our patients.

Download a comparative examination here.

See also:

]]> Tue, 30 Aug 2011 08:15:00 -0400 http://feedproxy.google.com/~r/private-practice/~3/ueGP-5ywMbU/apixaban-vs-rivaroxaban-vs-dabigatran-vs-warfarin http://blogs.theheart.org/private-practice/2011/8/30/apixaban-vs-rivaroxaban-vs-dabigatran-vs-warfarin http://blogs.theheart.org/private-practice/2011/8/30/apixaban-vs-rivaroxaban-vs-dabigatran-vs-warfarin#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/apixaban-vs-rivaroxaban-vs-dabigatran-vs-warfarin.jpg 14 ESC 2011 ESC 2011 http://blogs.theheart.org/private-practice/2011/8/30/apixaban-vs-rivaroxaban-vs-dabigatran-vs-warfarin Why is warfarin still holding strong? Private practice with Dr Seth Bilazarian info@theheart.org Despite the exciting results of the novel anticoagulants—including those for apixaban announced yesterday in Paris—warfarin continues to dominate the market as shown by the slow uptake of dabigatran. Why?<img src="http://feeds.feedburner.com/~r/private-practice/~4/lA97TjNc1hk" height="1" width="1"/> Despite the exciting results of the novel anticoagulants—including those for apixaban announced in Paris—warfarin continues to dominate the market as shown by the slow uptake of dabigatran. Why?

See also:

 

]]> Mon, 29 Aug 2011 09:15:00 -0400 http://feedproxy.google.com/~r/private-practice/~3/lA97TjNc1hk/apixaban-in-aristotle-at-esc-2011 http://blogs.theheart.org/private-practice/2011/8/28/apixaban-in-aristotle-at-esc-2011 http://blogs.theheart.org/private-practice/2011/8/28/apixaban-in-aristotle-at-esc-2011#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/apixaban-in-aristotle-at-esc-2011.jpg 1 ESC 2011 ESC 2011 http://blogs.theheart.org/private-practice/2011/8/28/apixaban-in-aristotle-at-esc-2011 Adopting dabigatran (Pradaxa): The pros and the cons Private practice with Dr Seth Bilazarian info@theheart.org As we eagerly await the details of the ARISTOTLE trial to learn how apixaban faired against warfarin, it's a good time to look at the advantages and disadvantages of dabigatran—which along with rivaroxaban and apixaban is vying to dethrone warfarin.<img src="http://feeds.feedburner.com/~r/private-practice/~4/_bWV-aHhq-o" height="1" width="1"/> As we eagerly await the details of the ARISTOTLE trial to learn how apixaban faired against warfarin, it's a good time to look at the advantages and disadvantages of dabigatran—which along with rivaroxaban and apixaban is vying to dethrone warfarin.

What has been your clinical experience with dabigatran?

See also:

 

]]> Wed, 24 Aug 2011 09:55:00 -0400 http://feedproxy.google.com/~r/private-practice/~3/_bWV-aHhq-o/adopting-dabigatran-pradaxa-the-pros-and-the-cons http://blogs.theheart.org/private-practice/2011/8/24/adopting-dabigatran-pradaxa-the-pros-and-the-cons http://blogs.theheart.org/private-practice/2011/8/24/adopting-dabigatran-pradaxa-the-pros-and-the-cons#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/adopting-dabigatran-pradaxa-the-pros-and-the-cons.jpg 0 ESC 2011 ESC 2011 http://blogs.theheart.org/private-practice/2011/8/24/adopting-dabigatran-pradaxa-the-pros-and-the-cons Adopting ticagrelor (Brilinta): The pros and the cons Private practice with Dr Seth Bilazarian info@theheart.org Adopting ticagrelor (Brilinta): The pros and the cons. There are compelling reasons for immediately adopting Brilinta into your practice, but they stack up against equally convincing arguments for postponing its use.<img src="http://feeds.feedburner.com/~r/private-practice/~4/rPtD2fitIQU" height="1" width="1"/> There are compelling reasons for immediately adopting Brilinta into your practice, but they stack up against equally convincing arguments for postponing its use.

How will you be adopting Brilinta?

See also:

Ticagrelor approval: US and Europe react

Ticagrelor approved at last for US market

]]> Fri, 29 Jul 2011 13:30:00 -0400 http://feedproxy.google.com/~r/private-practice/~3/rPtD2fitIQU/adopting-ticagrelor-brilinta-the-pros-and-the-cons http://blogs.theheart.org/private-practice/2011/7/29/adopting-ticagrelor-brilinta-the-pros-and-the-cons http://blogs.theheart.org/private-practice/2011/7/29/adopting-ticagrelor-brilinta-the-pros-and-the-cons#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/adopting-ticagrelor-brilinta-the-pros-and-the-cons.jpg 3 http://blogs.theheart.org/private-practice/2011/7/29/adopting-ticagrelor-brilinta-the-pros-and-the-cons Making bariatric surgery standard of practice Private practice with Dr Seth Bilazarian info@theheart.org Despite lingering clinical questions—most importantly, about whether there is a mortality benefit—bariatric surgery has shown excellent outcomes for patients with a body mass index of 35 kg/m2 or above who also have accompanying comorbidities.<img src="http://feeds.feedburner.com/~r/private-practice/~4/ruBZxH1jY10" height="1" width="1"/> Despite lingering clinical questions—most importantly, about whether there is a mortality benefit—bariatric surgery has shown excellent outcomes for patients with a body mass index of 35 kg/m2 or above who also have accompanying comorbidities. Do you think bariatric surgery (or at least referral for discussion at a center that performs the procedure) should be a standard of practice for such patients?

See also:

Bariatric surgery reduces long-term MI risk in men, but not women  

Bariatric surgery does not improve survival  

Gastric bypass does more than just reduce weight

Episode #29: Obesity in America with Dr Thad Waites

Fat chance: How cardiologists can help tip the obesity scales

]]> Fri, 22 Jul 2011 16:20:00 -0400 http://feedproxy.google.com/~r/private-practice/~3/ruBZxH1jY10/making-bariatric-surgery-standard-of-practice-2 http://blogs.theheart.org/private-practice/2011/7/22/making-bariatric-surgery-standard-of-practice-2 http://blogs.theheart.org/private-practice/2011/7/22/making-bariatric-surgery-standard-of-practice-2#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/making-bariatric-surgery-standard-of-practice-2.jpg 3 http://blogs.theheart.org/private-practice/2011/7/22/making-bariatric-surgery-standard-of-practice-2 Simvastatin: Now what? Private practice with Dr Seth Bilazarian info@theheart.org Simvastatin: Now what? Finding the right path for patients on simvastatin in light of the recent FDA recommendation is a dilemma as we wade through the recommendation itself, manufacturer information, pharmacy letters, and media coverage.<img src="http://feeds.feedburner.com/~r/private-practice/~4/SUrRmBvWU3I" height="1" width="1"/> Finding the right path for patients on simvastatin in light of the recent FDA recommendation is a dilemma as we wade through the recommendation itself, manufacturer information, pharmacy letters, and media coverage. How do we manage the simvastatin/calcium-channel-blocker interaction? What is the best method to review patients' records? How will (soon to be) generic atorvastatin fit into the equation? What is your approach?

See also:

FDA restricts use of simvastatin 80 mg

]]> Tue, 05 Jul 2011 08:50:00 -0400 http://feedproxy.google.com/~r/private-practice/~3/SUrRmBvWU3I/simvastatin-now-what http://blogs.theheart.org/private-practice/2011/7/4/simvastatin-now-what http://blogs.theheart.org/private-practice/2011/7/4/simvastatin-now-what#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/simvastatin-now-what.jpg 7 http://blogs.theheart.org/private-practice/2011/7/4/simvastatin-now-what Where to from AIM-HIGH? Private practice with Dr Seth Bilazarian info@theheart.org Should we continue to pursue HDL therapy? Does the concept of treating for residual risk still make sense? Important questions are raised by the halting of the AIM-HIGH trial. What advice are you giving your patients?<img src="http://feeds.feedburner.com/~r/private-practice/~4/dVEvUo2CCEU" height="1" width="1"/> Should we continue to pursue HDL therapy? Does the concept of treating for residual risk still make sense? Important questions are raised by the halting of the AIM-HIGH trial. As we await the trial data, how have you modified your clinical practice? What advice are you giving your patients?

Disclosure: I was a clinical investigator for AIM-HIGH

See also:

AIM-HIGH Study Statement to (NLA) Members

Learning from AIM-HIGH

NIH pulls plug on AIM-HIGH trial with niacin

AIM-HIGH: Maybe we should still hold on to our HATS?

A snapshot of the cholesterol drug market

]]> Fri, 03 Jun 2011 10:40:00 -0400 http://feedproxy.google.com/~r/private-practice/~3/dVEvUo2CCEU/searching-high-and-low-where-to-from-aimhigh http://blogs.theheart.org/private-practice/2011/6/3/searching-high-and-low-where-to-from-aimhigh http://blogs.theheart.org/private-practice/2011/6/3/searching-high-and-low-where-to-from-aimhigh#comments Private practice with Dr Seth Bilazarian http://blogs.theheart.org/images/thumbnails/searching-high-and-low-where-to-from-aimhigh.jpg 2 http://blogs.theheart.org/private-practice/2011/6/3/searching-high-and-low-where-to-from-aimhigh